Federal health regulators have cleared a genetic test from Roche as a firstchoice screening option for cervical cancer It was a role previously reserved for the Pap smear the decadesold mainstay of womens health The Food and Drug Administration approved Roches cobas HPV test to detect the human Papillomavirus or HPV in women  and up HPV causes nearly all cases of cervical cancer Doctors already use such DNAbased tools as a followup to confirm Pap test results But Thursdays decision means Roche can now market its test as a firstchoice option for cervical cancer screening ahead of the Pap test Currently no major medical guidelines recommend HPV testing alone for cervical cancer screening Dr David Chelmow of Virginia Commonwealth University said physicians should hold off on using the test until medical societies can provide guidance on some key questions including how frequently it should be used Chelmow spoke on behalf of the American College of Obstetrics and Gynecology at the FDAs meeting to review the test last month Roche supported its bid for expanded marketing with study results suggesting genetic testing is more accurate and objective at identifying cancerous growths than the Pap smear which requires doctors to examine cervical cells under a microscope for signs of cancer The test detects  highrisk forms of HPV that can lead to cervical cancer The FDA approval comes despite pushback from public health advocates who warned regulators that approving the DNA test as an alternative to Pap could lead to confusion higher costs and overtreatment More than a dozen patient groups raised those concerns in a letter to the FDA last week Specifically they said HPVonly testing could lead to overtreatment of younger women who carry the virus but have little risk of developing actual cancer Most sexually active young people contract HPV though their bodies usually eliminate the virus within a few months Only yearslong infections develop into cancer